AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32194164 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive method using neuron‐specific enolase (NSE) and interval III value
Number of subjects: 83
Study 35316569 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombosis events (TE) during therapy for ALL
Number of subjects: 794
Study 35316569 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and non-O blood group as independent predictors of TE
Number of subjects: 794
Study 35316569 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction TE
Number of subjects: 794
Study 35316569 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis recommendation
Number of subjects: 794
Study 33034409 — intervention group
Group type: EXPERIMENTAL
Intervention: RNP stage
Number of subjects: 2374
Study 33034409 — intervention group
Group type: EXPERIMENTAL
Intervention: RNP stage and TRNPM staging system
Number of subjects: 2374
Study 33034409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms
Number of subjects: 2374
Study 37384061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic adjuvant chemotherapy (MAC) consisting of weekly methotrexate (15 mg/m2) and celecoxib (200 mg PO BD) for 18 months
Number of subjects: 137
Study 37384061 — intervention group
Group type: COMPARATOR
Intervention: Observation post-complete response
Number of subjects: 137
Study 33509019 — intervention group
Group type: EXPERIMENTAL
Intervention: Breviscapine (120 mg daily for 14 days)
Number of subjects: 12
Study 33509019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 34649982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CIMT
Number of subjects: 118
Study 34649982 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose CIMT
Number of subjects: 118
Study 34649982 — intervention group
Group type: COMPARATOR
Intervention: Usual Customary Treatment (UCT)
Number of subjects: 118
Study 34649982 — intervention group
Group type: EXPERIMENTAL
Intervention: All CIMT groups
Number of subjects: 118
Study 32596367 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 26
Study 32596367 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo treatment)
Number of subjects: 26
Study 33527884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 68
Study 33527884 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke unit care
Number of subjects: 68
Study 32597565 — intervention group
Group type: EXPERIMENTAL
Intervention: NBD regimen (sequential nephron blockade with diuretics)
Number of subjects: 140
Study 32597565 — intervention group
Group type: COMPARATOR
Intervention: RASB regimen (sequential renin-angiotensin system blockade)
Number of subjects: 140
Study 32930610 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Life Skills (CLS) program
Number of subjects: 159
Study 32930610 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 159
Study 33551347 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLA group (colloidal bismuth pectin 200 mg thrice a day, lansoprazole 30 mg twice a day, amoxicillin 1 g twice a day, antofloxacin 200 mg once a day)
Number of subjects: 290
Study 33551347 — intervention group
Group type: COMPARATOR
Intervention: LCLA group (levofloxacin 500 mg once a day)
Number of subjects: 290
Study 33551347 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLA group (with antofloxacin susceptible strains)
Number of subjects: 290
Study 33551347 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLA group (with antofloxacin resistant strains)
Number of subjects: 290
Study 33551347 — intervention group
Group type: EXPERIMENTAL
Intervention: LCLA group (with levofloxacin susceptible strains)
Number of subjects: 290
Study 33551347 — intervention group
Group type: EXPERIMENTAL
Intervention: LCLA group (with levofloxacin resistant strains)
Number of subjects: 290
Study 33551347 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLA group
Number of subjects: 290
Study 33551347 — intervention group
Group type: COMPARATOR
Intervention: LCLA group
Number of subjects: 290
Study 35920037 — intervention group
Group type: EXPERIMENTAL
Intervention: High cotinine levels in smokers with brain aneurysm
Number of subjects: 86
Study 35920037 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 86
Study 35920037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine levels
Number of subjects: 86
Study 35920037 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 86
Study 34102583 — intervention group
Group type: COMPARATOR
Intervention: TV ad
Number of subjects: 7985
Study 34102583 — intervention group
Group type: EXPERIMENTAL
Intervention: TV ad + Keep count of your drinks PBS
Number of subjects: 7985
Study 32546648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years) / Goserelin (3 years)
Number of subjects: 488
Study 32546648 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) (6 cycles)
Number of subjects: 488
Study 33715300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (IG1) - education by trained peer educators
Number of subjects: 90
Study 33715300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (IG2) - education by a health practitioner
Number of subjects: 90
Study 33715300 — intervention group
Group type: COMPARATOR
Intervention: Comparison Group (CG) - no specific intervention mentioned
Number of subjects: 90
Study 32710602 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS)
Number of subjects: 70
Study 32710602 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS below −10 cm/s
Number of subjects: 70
Study 32710602 — intervention group
Group type: COMPARATOR
Intervention: GLS above −10 cm/s
Number of subjects: 70
Study 32710602 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS ≥ 17 cm/s
Number of subjects: 70
Study 36170550 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 318
Study 36170550 — intervention group
Group type: COMPARATOR
Intervention: Weight loss alone
Number of subjects: 318
Study 36170550 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus weight loss
Number of subjects: 318
Study 36170550 — intervention group
Group type: COMPARATOR
Intervention: Weight loss alone (among participants with elevated CRP at baseline)
Number of subjects: 318
Study 36170550 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus weight loss (among participants with elevated CRP at baseline)
Number of subjects: 318
Study 33626197 — intervention group
Group type: EXPERIMENTAL
Intervention: FLUGA (fludarabine, cytarabine, and filgrastim)
Number of subjects: 283
Study 33626197 — intervention group
Group type: COMPARATOR
Intervention: AZA (azacitidine)
Number of subjects: 283
Study 32726200 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositivity testing
Number of subjects: 1075
Study 34308678 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat therapy
Number of subjects: 117
Study 34308678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold rub gel
Number of subjects: 117
Study 34308678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 33404695 — intervention group
Group type: EXPERIMENTAL
Intervention: Low monoenergetic DECT images
Number of subjects: 50
Study 33404695 — intervention group
Group type: COMPARATOR
Intervention: Conventional DECT images
Number of subjects: 50
Study 36099876 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid with Sodium Ferrous Citrate (5-ALA + SFC)
Number of subjects: 74
Study 34015020 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning prediction model for waiting time to kidney transplant
Number of subjects: 48153
Study 34015020 — intervention group
Group type: COMPARATOR
Intervention: Cox regression model
Number of subjects: 48153
Study 32690050 — intervention group
Group type: EXPERIMENTAL
Intervention: High personal relevance: personal autobiographical photographs
Number of subjects: 240
Study 32690050 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium personal relevance: pictures of favourite locations associated with specific positive autobiographical memories
Number of subjects: 240
Study 32690050 — intervention group
Group type: COMPARATOR
Intervention: Low personal relevance: positive images from the International Affective Picture System
Number of subjects: 240
Study 36084714 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially Covered Double Bare Self-expandable Metal Stent (PCDBS)
Number of subjects: 258
Study 36084714 — intervention group
Group type: COMPARATOR
Intervention: Uncovered Double Bare Self-expandable Metal Stent (UCDBS)
Number of subjects: 258
Study 36084714 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy after stent placement
Number of subjects: 258
Study 33675226 — intervention group
Group type: EXPERIMENTAL
Intervention: liquid MVA given subcutaneously (liquid-SC group)
Number of subjects: 523
Study 33675226 — intervention group
Group type: EXPERIMENTAL
Intervention: liquid MVA given intradermally (liquid-ID group)
Number of subjects: 523
Study 33675226 — intervention group
Group type: EXPERIMENTAL
Intervention: lyophilized MVA given subcutaneously
Number of subjects: 523
Study 33675226 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 523
Study 32176092 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine Shenqi Compound
Number of subjects: 60
Study 32176092 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment combined with Chinese medicine placebo
Number of subjects: 60
Study 33563012 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 182
Study 33563012 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 182
Study 36286839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once a day
Number of subjects: 4304
Study 36286839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 35947804 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide plus rituximab (R2)
Number of subjects: 0
Study 35947804 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus chemotherapy (R-chemo)
Number of subjects: 0
Study 33588801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metformin 500 mg twice daily for 72 hours
Number of subjects: 103
Study 33588801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 34532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg/day
Number of subjects: 40
Study 34532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day
Number of subjects: 40
Study 34532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg/day
Number of subjects: 40
Study 34532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (all doses)
Number of subjects: 40
Study 33226907 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity ceramic tile model
Number of subjects: 36
Study 33226907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-fidelity 3D printed canine skull model
Number of subjects: 36
Study 33226907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity canine head model
Number of subjects: 36
Study 33226907 — intervention group
Group type: EXPERIMENTAL
Intervention: All models
Number of subjects: 36
Study 33226907 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D skull and full head models
Number of subjects: 36
Study 36468403 — intervention group
Group type: EXPERIMENTAL
Intervention: Active BP lowering treatment (combination perindopril±indapamide)
Number of subjects: 10885
Study 33476415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution same-day dose (n=200)
Number of subjects: 602
Study 33476415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution split-dose (n=202)
Number of subjects: 602
Study 33476415 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol plus ascorbate (n=200)
Number of subjects: 602
Study 36484364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (3 times per week during irradiation, diode laser: 660 nm, 75 mW, 1.5 cm2, 50 mW/cm2, 60 seconds exposure, 3 J/cm2, 20-30 spots per session)
Number of subjects: 87
Study 36484364 — intervention group
Group type: COMPARATOR
Intervention: Sham low-level laser therapy (identical delivery method to low-level laser therapy)
Number of subjects: 87
Study 33639454 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel exercises
Number of subjects: 60
Study 33639454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Kegel exercises)
Number of subjects: 60
Study 32784153 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded Dix-Hallpike (L-DH)
Number of subjects: 28
Study 32784153 — intervention group
Group type: COMPARATOR
Intervention: Standard Dix-Hallpike (S-DH)
Number of subjects: 28
Study 36111892 — intervention group
Group type: EXPERIMENTAL
Intervention: trCTCs positive patients
Number of subjects: 33
Study 36111892 — intervention group
Group type: COMPARATOR
Intervention: trCTCs negative patients
Number of subjects: 33
Study 36111892 — intervention group
Group type: EXPERIMENTAL
Intervention: trCTCs positivity
Number of subjects: 33
Study 36111892 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year postoperative trCTCs positivity
Number of subjects: 33
Study 36111892 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating clinicopathological features with trCTCs
Number of subjects: 33
Study 36317751 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR4640 (10 mg) under fed conditions
Number of subjects: 14
Study 36317751 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR4640 (10 mg) under fasted conditions
Number of subjects: 14
Study 36317751 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR4640 (10 mg)
Number of subjects: 14
Study 33753349 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine IMPACT Plus intervention (multi-provider case conference with follow-up)
Number of subjects: 163
Study 33753349 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 163
Study 32853584 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg orally daily from 21 days preoperatively to postoperative day 7
Number of subjects: 74
Study 32853584 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin 1 g/kg or 2 g/kg 7 days before surgery
Number of subjects: 74
Study 32853584 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (per-protocol analysis)
Number of subjects: 74
Study 32853584 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (per-protocol analysis)
Number of subjects: 74
Study 35768027 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment received aligned with recommendations
Number of subjects: 108
Study 35768027 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant treatment recommendations
Number of subjects: 108
Study 35768027 — intervention group
Group type: EXPERIMENTAL
Intervention: Urologists' and radiation oncologists' treatment recommendations
Number of subjects: 108
Study 32464351 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of 5-Hydroxytryptophan (5-HTP) daily
Number of subjects: 12
Study 32464351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35229404 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 0
Study 35229404 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 0
Study 34727839 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual SDOH variables (fewer years of education, lower income)
Number of subjects: 664
Study 34727839 — intervention group
Group type: EXPERIMENTAL
Intervention: Community SDOH (lower rates of health insurance, lower income, greater income inequality)
Number of subjects: 664
Study 35176190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium propionate (SP) supplementation for 12 weeks
Number of subjects: 32
Study 34521208 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual placement and support (IPS) (N=58)
Number of subjects: 119
Study 34521208 — intervention group
Group type: COMPARATOR
Intervention: Standard VHA non‐IPS vocational rehabilitation (VR) (N=61)
Number of subjects: 119
Study 34521208 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 119
Study 35683586 — intervention group
Group type: EXPERIMENTAL
Intervention: Core training program (six weeks, three times/week) with regular swimming training
Number of subjects: 18
Study 35683586 — intervention group
Group type: EXPERIMENTAL
Intervention: Core training program
Number of subjects: 18
Study 35683586 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular training)
Number of subjects: 18
Study 32600474 — intervention group
Group type: EXPERIMENTAL
Intervention: Choledochojejunostomy
Number of subjects: 210
Study 32600474 — intervention group
Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 210
Study 33990951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 846
Study 33990951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 846
Study 33990951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 846
Study 33990951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study 34727753 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice awareness communication present
Number of subjects: 684
Study 34727753 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician preference communication present
Number of subjects: 684
Study 34727753 — intervention group
Group type: COMPARATOR
Intervention: Choice awareness communication absent
Number of subjects: 684
Study 34727753 — intervention group
Group type: COMPARATOR
Intervention: Physician preference communication absent
Number of subjects: 684
Study 34666470 — intervention group
Group type: EXPERIMENTAL
Intervention: IONM combined with 'classification of EBSLN' in experimental group
Number of subjects: 827
Study 34666470 — intervention group
Group type: COMPARATOR
Intervention: Control group (ligation of branches of the superior thyroid vessels without attempts to visually identify the nerve)
Number of subjects: 827
Study 32919383 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a multistrategy intervention to improve teachers' implementation of a school physical activity policy
Number of subjects: 1502
Study 36457123 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational support intervention including peer groups for infant care
Number of subjects: 0
Study 36457123 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34229295 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-morbid insomnia and sleep apnea (COMISA)
Number of subjects: 0
Study 34229295 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological research, case studies, single-arm treatment studies, randomized controlled treatment trials, and objective sleep study data
Number of subjects: 0
Study 33749219 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed freehand by experienced clinicians
Number of subjects: 77
Study 33749219 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc planning versus actual placement
Number of subjects: 77
Study 33017456 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g/day low-carbohydrate diet (LCD)
Number of subjects: 92
Study 33017456 — intervention group
Group type: COMPARATOR
Intervention: traditional diabetic diet (TDD)
Number of subjects: 92
Study 33184632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy diet (3.3 servings/d)
Number of subjects: 72
Study 33184632 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat dairy diet (3.3 servings/d)
Number of subjects: 72
Study 33184632 — intervention group
Group type: COMPARATOR
Intervention: Limited dairy diet (≤3 servings/wk of nonfat milk)
Number of subjects: 72
Study 33184632 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat dairy diet
Number of subjects: 72
Study 33184632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy diet
Number of subjects: 72
Study 32172599 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART) adherence strategies
Number of subjects: 527
Study 32172599 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level strategies to improve adherence
Number of subjects: 527
Study 32172599 — intervention group
Group type: EXPERIMENTAL
Intervention: Family- or community-level interventions
Number of subjects: 527
Study 32195538 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily isocaloric meal with standardized amount of avocado (males: 175 g; females: 140 g) for 12 weeks
Number of subjects: 115
Study 32195538 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily isocaloric meal with standardized amount of avocado
Number of subjects: 115
Study 32195538 — intervention group
Group type: COMPARATOR
Intervention: Control meals (without avocado)
Number of subjects: 115
Study 35602971 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (30 g, b.i.d. for 21 days)
Number of subjects: 32
Study 35602971 — intervention group
Group type: COMPARATOR
Intervention: Microcrystalline cellulose (placebo, 30 g, b.i.d. for 21 days)
Number of subjects: 32
Study 35602971 — intervention group
Group type: COMPARATOR
Intervention: Rice protein (placebo, 30 g, b.i.d. for 21 days)
Number of subjects: 32
Study 35086759 — intervention group
Group type: EXPERIMENTAL
Intervention: FIPELS group (10 patients)
Number of subjects: 20
Study 35086759 — intervention group
Group type: EXPERIMENTAL
Intervention: FIPELS group with palatal speech appliance (10 patients)
Number of subjects: 20
Study 35086759 — intervention group
Group type: COMPARATOR
Intervention: Traditional flap design group (10 patients)
Number of subjects: 20
Study 34391828 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins treatment
Number of subjects: 0
Study 34391828 — intervention group
Group type: COMPARATOR
Intervention: Intensive therapy combined with statins
Number of subjects: 0
Study 32174572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Number of subjects: 184
Study 32174572 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 1.0%
Number of subjects: 184
Study 35105643 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 68